RecruitingNCT06410976
Prospective Clinical Assessment Study in Children With Hypochondroplasia
Prospective Clinical Assessment Study in Children With Hypochondroplasia: ACCEL
Sponsor
QED Therapeutics, a BridgeBio company
Enrollment
150 participants
Start Date
Jun 5, 2024
Study Type
OBSERVATIONAL
Conditions
Summary
This is a long-term, multicenter, non-interventional study of children ages 2.5 to \<17 years with hypochondroplasia (HCH).
Eligibility
Min Age: 30 MonthsMax Age: 16 Years
Plain Language Summary
Simplified for easier understanding
This clinical trial is studying a new treatment for people with hypochondroplasia. The study is currently recruiting participants at 25 locations. People eligible for this study include aged 30 Months to 16 Years.
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Locations(25)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06410976
Related Trials
A Study of Vosoritide Versus Placebo in Children With Hypochondroplasia Aged 0 to < 36 Months
NCT0712626226 locations
Prospective Longitudinal Monocentric Study to Measure Limb Movement in Patients With FGFR3-related Skeletal Dysplasia
NCT073889661 location
A Multicenter Multinational Observational Study of Children With Hypochondroplasia
NCT0621294743 locations
Registry for Patients With Achondroplasia / Hypochondroplasia (OMPR-Ach/Hy)
NCT053280501 location